Kythera Biopharmaceuticals, Inc. (KYTH) Thursday reported a wider loss for the fourth quarter, due mainly to higher expenses.
Net loss for the quarter widened to $18.04 million or $1.04 per share from $5.63 million or $0.44 per share in the same period last year.
Operating expenses jumped to $17.78 million from $8.12 million last year. Research and development totaled $14.38 million, up from $6.17 million last year.
For comments and feedback: editorial@rttnews.com